Immunotherapy-based treatments, including immune checkpoint inhibitors (ICIs) typified by anti-PD-1/PD-L1 drugs, can re-activate immune cells by blocking immune checkpoints in cancer patients, so CD8+ T cytotoxicity against tumor cells can be restored [90]. This evidence concerns the gene CD8A and cancer.